bioMérieux S.A.
bioMérieux S.A.
Your view on BMXXY
Overview
What the company does, where it operates, and who runs it.
About bioMérieux S.A.
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- CEO
- Pierre Boulud
- Headquarters
- 376 Chemin De l’Orme, Marcy l'Étoile, FR
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- CEO
- Pierre Boulud
- Headquarters
- 376 Chemin De l’Orme, Marcy l'Étoile, FR
bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.
The company offers systems, which use biological samples to diagnose infectious diseases, cardiovascular pathologies, and various cancers; and microbiological testing of manufacturing primarily for food, pharmaceutical, cosmetics, and veterinary sectors.
It serves clinical and hospital laboratories, physicians, blood banks, and industrial control laboratories. The company was formerly known as B-D Mérieux. bioMérieux S.A. was founded in 1963 and is headquartered in Marcy l'Etoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for bioMérieux S.A., and the rating behind it. BMXXY last traded at $14.55, 17.9× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for bioMérieux S.A.. Starting points for bioMérieux S.A.: P/E 17.9, EPS $0.39, beta 0.66 — an Medical - Diagnostics & Research name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for bioMérieux S.A.. bioMérieux S.A. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for bioMérieux S.A.. Trailing twelve-month EPS for bioMérieux S.A. stands at $0.39. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for bioMérieux S.A.. bioMérieux S.A. has reported as a listed company since 2023. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
bioMérieux S.A. valued side by side against its closest peers. bioMérieux S.A. is measured against Medical - Diagnostics & Research peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold bioMérieux S.A., and how their positions are changing. At a $17.18B market value, institutional positions materially move bioMérieux S.A.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by bioMérieux S.A. executives and directors. Shares of bioMérieux S.A. have traded between $9.51 and $14.62 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming bioMérieux S.A.. bioMérieux S.A. is a $17.18B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming bioMérieux S.A.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for bioMérieux S.A.. Coverage tracks bioMérieux S.A. within Medical - Diagnostics & Research (Healthcare). Press releases and market coverage, newest first.